Biomedicine & Pharmacotherapy,
Journal Year:
2024,
Volume and Issue:
177, P. 116930 - 116930
Published: June 14, 2024
The
tumor
microenvironment
(TME)
is
a
combination
of
cells
and
indigenous
host
stroma,
which
consists
tumor-infiltrating
immune
cells,
endothelial
fibroblasts,
pericytes,
non-cellular
elements.
Tumor-associated
macrophages
(TAMs)
represent
the
major
cell
type
are
generally
polarized
into
two
functionally
contradictory
subtypes,
namely
classical
activated
M1
alternatively
M2
macrophages.
Macrophage
polarization
refers
to
how
at
given
time
space.
interplay
between
TME
macrophage
can
influence
initiation
progression,
making
TAM
potential
target
for
cancer
therapy.
Here,
we
review
latest
investigations
on
factors
orchestrating
in
TME,
affects
perspectives
modulating
immunotherapy.
ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(4), P. 3225 - 3258
Published: Feb. 6, 2023
The
immune
checkpoint
blockade
(ICB)
therapy
has
revolutionized
the
field
of
cancer
treatment,
while
low
response
rates
and
systemic
toxicity
limit
its
clinical
outcomes.
With
rapid
advances
in
nanotechnology
materials
science,
various
types
biomaterials
have
been
developed
to
maximize
therapeutic
efficacy
minimizing
side
effects
by
increasing
tumor
antigenicity,
reversing
immunosuppressive
microenvironment,
amplifying
antitumor
response,
reducing
extratumoral
distribution
inhibitors
as
well
enhancing
their
retention
within
target
sites.
In
this
review,
we
reviewed
current
design
strategies
for
different
augment
ICB
effectively
then
discussed
present
representative
biomaterial-assisted
modulation
targeted
delivery
boost
therapy.
Current
challenges
future
development
prospects
expanding
with
were
also
summarized.
We
anticipate
review
will
be
helpful
developing
emerging
promoting
application
Advanced Materials,
Journal Year:
2023,
Volume and Issue:
35(12)
Published: Jan. 19, 2023
Although
immunotherapy
has
revolutionized
oncotherapy,
only
≈15%
of
head
and
neck
squamous
cell
carcinoma
(HNSCC)
patients
benefit
from
the
current
therapies.
An
immunosuppressive
tumor
microenvironment
(TME)
dysregulation
polycomb
ring
finger
oncogene
BMI1
are
potential
reasons
for
failure.
Herein,
to
promote
immunotherapeutic
efficacy
against
HNSCC,
an
injectable
nanocomposite
hydrogel
is
developed
with
a
polymer
framework
(PLGA-PEG-PLGA)
that
loaded
both
imiquimod
encapsulated
CaCO3
nanoparticles
(RC)
cancer
membrane
(CCM)-coated
mesoporous
silica
containing
peptide-based
proteolysis-targeting
chimeras
(PROTAC)
paclitaxel
(PepM@PacC).
Upon
injection,
this
undergoes
in
situ
gelation,
after
which
it
degrades
TME
over
time,
releasing
RC
PepM@PacC
respectively
perform
chemotherapy.
Specifically,
particles
selectively
manipulate
tumor-associated
macrophages
dendritic
cells
activate
T-cell
immune
response,
while
CCM-mediated
homologous
targeting
endocytosis
delivers
into
cells,
where
endogenous
glutathione
promotes
disulfide
bond
cleavage
release
PROTAC
peptide
degradation
frees
particle
pores
elicit
apoptosis
meanwhile
enhance
immunotherapy.
Thus,
hydrogel,
designed
exploit
multiple
known
vulnerabilities
succeeds
suppressing
growth
metastasis
HNSCC.
Materials Today Bio,
Journal Year:
2023,
Volume and Issue:
20, P. 100633 - 100633
Published: April 12, 2023
With
the
development
of
nanotechnology,
nanoparticles
have
emerged
as
a
delivery
carrier
for
tumor
drug
therapy,
which
can
improve
therapeutic
effect
by
increasing
stability
and
solubility
prolonging
half-life
drugs.
However,
are
foreign
substances
humans,
easily
cleared
immune
system,
less
targeted
to
tumors,
may
even
be
toxic
body.
As
natural
biological
material,
cell
membranes
unique
properties,
such
good
biocompatibility,
strong
targeting
ability,
ability
evade
surveillance,
high
drug-carrying
capacity.
In
this
article,
we
review
membrane-coated
(CMNPs)
their
applications
therapy.
First,
briefly
describe
CMNP
characteristics
applications.
Second,
present
advantages
different
well
nanoparticles,
provide
brief
description
process
CMNPs,
discuss
current
status
application
summarize
shortcomings
use
in
cancer
propose
future
research
directions.
This
summarizes
progress
on
CMNPs
therapy
recent
years
assesses
remaining
problems,
providing
scholars
with
new
ideas
Biomedicine & Pharmacotherapy,
Journal Year:
2024,
Volume and Issue:
177, P. 116930 - 116930
Published: June 14, 2024
The
tumor
microenvironment
(TME)
is
a
combination
of
cells
and
indigenous
host
stroma,
which
consists
tumor-infiltrating
immune
cells,
endothelial
fibroblasts,
pericytes,
non-cellular
elements.
Tumor-associated
macrophages
(TAMs)
represent
the
major
cell
type
are
generally
polarized
into
two
functionally
contradictory
subtypes,
namely
classical
activated
M1
alternatively
M2
macrophages.
Macrophage
polarization
refers
to
how
at
given
time
space.
interplay
between
TME
macrophage
can
influence
initiation
progression,
making
TAM
potential
target
for
cancer
therapy.
Here,
we
review
latest
investigations
on
factors
orchestrating
in
TME,
affects
perspectives
modulating
immunotherapy.
